J. Taylor Whaley, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 1, 2014
Picture of an US machine
May 23, 2011 - The combined use of a CA-125 blood test and transvaginal ultrasound for early detection of ovarian cancer does not appear to reduce the risk of death from the disease in the general population, and harm may result from diagnostic evaluation performed after false-positive tests, according to research to be presented at the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.
May 23, 2011
Jun 23, 2010
Dec 19, 2014